Jan Weber

List of Publications by Year
in descending order

70 papers	2,391 citations	257450 24 h-index	214800 47 g-index
74 all docs	74 docs citations	74 times ranked	3849 citing authors

#	Article	IF	Citations
1	Human epithelial Î²-defensins 2 and 3 inhibit HIV-1 replication. Aids, 2003, 17, F39-F48.	2.2	388
2	Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nature Materials, 2018, 17, 195-203.	27.5	331
3	Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. FEBS Journal, 2001, 268, 2669-2677.	0.2	105
4	Use of Four Next-Generation Sequencing Platforms to Determine HIV-1 Coreceptor Tropism. PLoS ONE, 2012, 7, e49602.	2.5	78
5	Role of the Human Immunodeficiency Virus Type 1 Envelope Gene in Viral Fitness. Journal of Virology, 2003, 77, 9069-9073.	3.4	77
6	Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation. Journal of Clinical Microbiology, 2005, 43, 1395-1400.	3.9	76
7	Protective hybrid coating containing silver, copper and zinc cations effective against human immunodeficiency virus and other enveloped viruses. BMC Microbiology, 2016, 16, 56.	3.3	76
8	Increased Levels of Human Beta-Defensins mRNA in Sexually HIV-1 Exposed But Uninfected Individuals. Current HIV Research, 2008, 6, 531-538.	0.5	74
9	Highly Selective Phosphatidylinositol 4-Kinase IIIÎ² Inhibitors and Structural Insight into Their Mode of Action. Journal of Medicinal Chemistry, 2015, 58, 3767-3793.	6.4	54
10	Development of 5â€˜ LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals. Clinical Epigenetics, 2016, 8, 19.	4.1	54
11	Rational Design of Novel Highly Potent and Selective Phosphatidylinositol 4-Kinase IIIÎ² (PI4KB) Inhibitors as Broad-Spectrum Antiviral Agents and Tools for Chemical Biology. Journal of Medicinal Chemistry, 2017, 60, 100-118.	6.4	50
12	Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. Journal of Virological Methods, 2006, 136, 102-117.	2.1	47
13	Unusual Binding Mode of an HIV-1 Protease Inhibitor Explains its Potency against Multi-drug-resistant Virus Strains. Journal of Molecular Biology, 2002, 324, 739-754.	4.2	46
14	PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core. PLoS ONE, 2017, 12, e0186982.	2.5	42
15	Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation. Journal of Virology, 2002, 76, 10546-10552.	3.4	40
16	Current tests to evaluate HIV-1 coreceptor tropism. Current Opinion in HIV and AIDS, 2009, 4, 136-142.	3.8	40
17	A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. Journal of General Virology, 2003, 84, 2217-2228.	2.9	37
18	Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. PLoS ONE, 2016, 11, e0156063.	2.5	35

#	Article	IF	Citations
19	Polylactic acid as a suitable material for 3D printing of protective masks in times of COVID-19 pandemic. PeerJ, 2020, 8, e10259.	2.0	34
20	Multi-sulfonated ligands on gold nanoparticles as virucidal antiviral for Dengue virus. Scientific Reports, 2020, 10, 9052.	3.3	32
21	Viral Drug Resistance and Fitness. Advances in Pharmacology, 2008, 56, 257-296.	2.0	30
22	HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Reviews, 2006, 8, 60-77.	1.0	30
23	Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides. Antimicrobial Agents and Chemotherapy, 2011, 55, 1403-1413.	3.2	29
24	Synthesis and biological activity of benzo-fused 7-deazaadenosine analogues. 5- and 6-substituted 4-amino- or 4-alkylpyrimido[4,5-b]indole ribonucleosides. Bioorganic and Medicinal Chemistry, 2013, 21, 5362-5372.	3.0	26
25	The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells. Frontiers in Immunology, 2018, 9, 364.	4.8	26
26	Configurations of Diastereomeric Hydroxyethylene Isosteres Strongly Affect Biological Activities of a Series of Specific Inhibitors of Human-Immunodeficiency-Virus Proteinase. FEBS Journal, 1997, 250, 559-566.	0.2	25
27	Role of Baseline pol Genotype in HIV-1 Fitness Evolution. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 448-460.	2.1	25
28	Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor. Nature Communications, 2015, 6, 6461.	12.8	25
29	Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3â€²Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2011, 55, 3729-3742.	3.2	23
30	HIV type 1 integrase inhibitors: from basic research to clinical implications. AIDS Reviews, 2008, 10, 172-89.	1.0	23
31	Antiviral Activity of 7-Substituted 7-Deazapurine Ribonucleosides, Monophosphate Prodrugs, and Triphoshates against Emerging RNA Viruses. ACS Infectious Diseases, 2021, 7, 471-478.	3.8	22
32	LC/MS analysis and deep sequencing reveal the accurate RNA composition in the HIV-1 virion. Scientific Reports, 2019, 9, 8697.	3.3	21
33	Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors. European Journal of Medicinal Chemistry, 2020, 208, 112754.	5.5	21
34	Potency Comparison of Peptidomimetic Inhibitors against HIV-1 and HIV-2 Proteinases: Design of Equipotent Lead Compounds. Archives of Biochemistry and Biophysics, 1997, 341, 62-69.	3.0	18
35	A Picomolar Inhibitor of Resistant Strains of Human Immunodeficiency Virus Protease Identified by a Combinatorial Approach. Archives of Biochemistry and Biophysics, 2000, 382, 22-30.	3.0	18
36	Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism. Journal of Clinical Microbiology, 2013, 51, 1517-1527.	3.9	18

#	Article	IF	Citations
37	(Iso)Quinolineâ€“Artemisinin Hybrids Prepared through Click Chemistry: Highly Potent Agents against Viruses. Chemistry - A European Journal, 2020, 26, 12019-12026.	3.3	18
38	Synthesis and in vitro Study of Artemisinin/Synthetic Peroxideâ€Based Hybrid Compounds against SARSâ€CoVâ€2 and Cancer. ChemMedChem, 2022, 17, .	3.2	17
39	Can HIV-1 superinfection compromise antiretroviral therapy?. Aids, 2004, 18, 131-134.	2.2	16
40	Highly Functionalized and Potent Antiviral Cyclopentane Derivatives Formed by a Tandem Process Consisting of Organometallic, Transitionâ€Metalâ€Catalyzed, and Radical Reaction Steps. Chemistry - A European Journal, 2014, 20, 10298-10304.	3.3	15
41	Synthesis and biological profiling of 6- or 7-(het)aryl-7-deazapurine 4â€²-C-methylribonucleosides. Bioorganic and Medicinal Chemistry, 2015, 23, 7422-7438.	3.0	15
42	Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Scientific Reports, 2020, 10, 12767.	3.3	14
43	Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs. Journal of Clinical Microbiology, 2009, 47, 2232-2242.	3.9	13
44	Hepatitis B Core Protein Is Post-Translationally Modified through K29-Linked Ubiquitination. Cells, 2020, 9, 2547.	4.1	13
45	Discovery of Modified Amidate (ProTide) Prodrugs of Tenofovir with Enhanced Antiviral Properties. Journal of Medicinal Chemistry, 2021, 64, 16425-16449.	6.4	13
46	Contribution of Human Immunodeficiency Virus Type 1 Minority Variants to Reduced Drug Susceptibility in Patients on an Integrase Strand Transfer Inhibitor-Based Therapy. PLoS ONE, 2014, 9, e104512.	2.5	12
47	Purine analogs as phosphatidylinositol 4-kinase IIIÎ² inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2706-2712.	2.2	12
48	Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation. Scientific Reports, 2018, 8, 10438.	3.3	12
49	Localization of SARS-CoV-2 Capping Enzymes Revealed by an Antibody against the nsp10 Subunit. Viruses, 2021, 13, 1487.	3.3	12
50	Resistance Mutations outside the Integrase Coding Region Have an Effect on Human Immunodeficiency Virus Replicative Fitness but Do Not Affect Its Susceptibility to Integrase Strand Transfer Inhibitors. PLoS ONE, 2013, 8, e65631.	2.5	10
51	Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system. Antiviral Research, 2011, 91, 94-98.	4.1	9
52	Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Research and Therapy, 2017, 14, 15.	1.7	9
53	Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations. Current Opinion in HIV and AIDS, 2007, 2, 81-87.	3.8	7
54	Natural Apocarotenoids and Their Synthetic Glycopeptide Conjugates Inhibit SARS-CoV-2 Replication. Pharmaceuticals, 2021, 14, 1111.	3.8	7

#	Article	IF	Citations
55	Impact on Replicative Fitness of the G48E Substitution in the Protease of HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 255-262.	2.1	6
56	Does BCA3 Play a Role in the HIV-1 Replication Cycle?. Viruses, 2018, 10, 212.	3.3	6
57	Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5. Antiviral Research, 2019, 164, 81-90.	4.1	6
58	The impact of viral and host elements on HIV fitness and disease progression. Current HIV/AIDS Reports, 2007, 4, 36-41.	3.1	5
59	Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity. Archiv Der Pharmazie, 2017, 350, 1700020.	4.1	5
60	structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor. Antiviral Research, 2021, 185, 104971.	4.1	5
61	Synthesis and evaluation of 2-pyridinylpyrimidines as inhibitors of HIV-1 structural protein assembly. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3487-3490.	2.2	4
62	Expression of TIM-3 on Plasmacytoid Dendritic Cells as a Predictive Biomarker of Decline in HIV-1 RNA Level during ART. Viruses, 2018, 10, 154.	3.3	4
63	Decontamination of High-Efficiency Mask Filters From Respiratory Pathogens Including SARS-CoV-2 by Non-thermal Plasma. Frontiers in Bioengineering and Biotechnology, 2022, 10, 815393.	4.1	4
64	TLR4-Mediated Recognition of Mouse Polyomavirus Promotes Cancer-Associated Fibroblast-Like Phenotype and Cell Invasiveness. Cancers, 2021, 13, 2076.	3.7	3
65	Triterpenoidâ€“PEG Ribbons Targeting Selectivity in Pharmacological Effects. Biomedicines, 2021, 9, 951.	3.2	3
66	Peptide Inhibitors of Aspartic Proteinases with Hydroxyethylene Isostere Replacement of Peptide Bond. II. Preparation of Pseudotetrapeptides Derived from Diastereoisomeric 5-Amino-2-benzyl-4-hydroxy-6-phenylhexanoic Acids. Collection of Czechoslovak Chemical Communications, 1998, 63, 541-548.	1.0	3
67	A Helquat-like Compound as a Potent Inhibitor of Flaviviral and Coronaviral Polymerases. Molecules, 2022, 27, 1894.	3.8	3
68	ATM-Dependent Phosphorylation of Hepatitis B Core Protein in Response to Genotoxic Stress. Viruses, 2021, 13, 2438.	3.3	3
69	Biogenesis of hepatitis B virus e antigen is driven by transloconâ€associated protein complex and regulated by conserved cysteine residues within its signal peptide sequence. FEBS Journal, 2022, 289, 2895-2914.	4.7	2
70	Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides. Antimicrobial Agents and Chemotherapy, 2011, 55, 3645-3645.	3.2	0